AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29533112 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated contralateral flanks)
Number of subjects: 0
Study 29528419 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) of the resection cavity and single- or multisession SRT of all unresected brain metastases (up to 10 lesions)
Number of subjects: 50
Study 29528419 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 50
Study 26854906 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313 (low dose)
Number of subjects: 30
Study 26854906 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313 (standard dose)
Number of subjects: 30
Study 26854906 — intervention group
Group type: COMPARATOR
Intervention: MVA85A
Number of subjects: 30
Study 26854906 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A-IMX313
Number of subjects: 30
Study 24401829 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback of movement-associated cortical activity (beta band 16-28 Hz) using a brain-computer interface (BCI) system during mental practice training.
Number of subjects: 10
Study 24401829 — intervention group
Group type: COMPARATOR
Intervention: No EEG cortical feedback during mental practice training.
Number of subjects: 10
Study 23147404 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular closure of the PFO
Number of subjects: 0
Study 23147404 — intervention group
Group type: COMPARATOR
Intervention: Non-PFO-related ischemic stroke
Number of subjects: 0
Study 19764180 — intervention group
Group type: EXPERIMENTAL
Intervention: Legislative effort to prevent falls from height in construction
Number of subjects: 0
Study 17177960 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg transcutaneous patch)
Number of subjects: 12
Study 17177960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16000961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (3 x 10(6) IU/m2/d) administered subcutaneously for 42 days
Number of subjects: 93
Study 12387527 — intervention group
Group type: EXPERIMENTAL
Intervention: N 25 mg
Number of subjects: 45
Study 12387527 — intervention group
Group type: EXPERIMENTAL
Intervention: N 50 mg
Number of subjects: 45
Study 12387527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9814633 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale (GOS)
Number of subjects: 0
Study 9814633 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability Rating Scale (DRS)
Number of subjects: 0
Study 9814633 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between DRS and GOS
Number of subjects: 0
Study 8137624 — intervention group
Group type: EXPERIMENTAL
Intervention: GES/EE (gestodene 75 mcg/ethinyl oestradiol 30 mcg)
Number of subjects: 1006
Study 8137624 — intervention group
Group type: COMPARATOR
Intervention: DES/EE (desogestrel 150 mcg/ethinyl oestradiol 20 mcg)
Number of subjects: 1006
Study 8137624 — intervention group
Group type: EXPERIMENTAL
Intervention: GES/EE
Number of subjects: 1006
Study 8137624 — intervention group
Group type: COMPARATOR
Intervention: DES/EE
Number of subjects: 1006
Study 2536537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of calcitriol
Number of subjects: 0
Study 2536537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of active forms of vitamin D3
Number of subjects: 0
Study 2536537 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal serum level of 1 alpha,25‐dihydroxyvitamin D
Number of subjects: 0
Study 2536537 — intervention group
Group type: EXPERIMENTAL
Intervention: Other calcium‐related parameters
Number of subjects: 0
Study 30279219 — intervention group
Group type: EXPERIMENTAL
Intervention: '11+ Kids' injury prevention programme (INT)
Number of subjects: 0
Study 30279219 — intervention group
Group type: COMPARATOR
Intervention: Regular training regime (CON)
Number of subjects: 0
Study 29168959 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program on neonatal care (3 sessions)
Number of subjects: 116
Study 29168959 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 116
Study 25330801 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIEF pathway
Number of subjects: 1555
Study 25330801 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk alleles
Number of subjects: 1555
Study 22995539 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/DNG oral contraceptive
Number of subjects: 100
Study 21774987 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month socioculturally adapted collaborative care (psychotherapy and/or antidepressants, telephone symptom monitoring/relapse prevention)
Number of subjects: 387
Study 21774987 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month socioculturally adapted collaborative care
Number of subjects: 387
Study 19631861 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE ACUSEAL patch
Number of subjects: 200
Study 19631861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemashield Finesse patch
Number of subjects: 200
Study 19631861 — intervention group
Group type: COMPARATOR
Intervention: PTFE ACUSEAL patch and Hemashield Finesse patch
Number of subjects: 200
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in technique (group A)
Number of subjects: 57
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out technique (group B)
Number of subjects: 57
Study 16858558 — intervention group
Group type: COMPARATOR
Intervention: All-inside technique (group C)
Number of subjects: 57
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time for group A
Number of subjects: 57
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time for group B
Number of subjects: 57
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time for group C
Number of subjects: 57
Study 16858558 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications among groups
Number of subjects: 57
Study 15213476 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nursing intervention (12 consecutive weekly meetings)
Number of subjects: 155
Study 15213476 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation program (control group)
Number of subjects: 155
Study 12237729 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 12237729 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fibrinolytics
Number of subjects: 0
Study 12237729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (intraoperative use)
Number of subjects: 0
Study 12237729 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP
Number of subjects: 0
Study 12237729 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous predonation
Number of subjects: 0
Study 9641732 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily growth hormone injection (group A)
Number of subjects: 49
Study 9641732 — intervention group
Group type: COMPARATOR
Intervention: Twice daily growth hormone injections (group B)
Number of subjects: 49
Study 7853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group A
Number of subjects: 49
Study 7853436 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group B
Number of subjects: 49
Study 7853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group B
Number of subjects: 49
Study 7853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole treatment in Group C
Number of subjects: 49
Study 7853436 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group D
Number of subjects: 49
Study 2910422 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusor (Baxter Healthcare Corporation) for outpatient CVI chemotherapy
Number of subjects: 22
Study 2910422 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient CVI chemotherapy delivery device (standard pump)
Number of subjects: 22
Study 2910422 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusor (Baxter Healthcare Corporation) for inpatient CVI chemotherapy
Number of subjects: 22
Study 2910422 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient CVI chemotherapy
Number of subjects: 22
Study 2910422 — intervention group
Group type: EXPERIMENTAL
Intervention: CVI chemotherapy (both methods)
Number of subjects: 22
Study 1130305 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (small daily dose)
Number of subjects: 431
Study 1130305 — intervention group
Group type: EXPERIMENTAL
Intervention: Food fortification with folic acid
Number of subjects: 431
Study 26014293 — intervention group
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 436
Study 26014293 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 436
Study 22959620 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (6 g, two daily doses)
Number of subjects: 100
Study 22959620 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 100
Study 21292332 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid antibiotic pack (Betnovate-N: betnovate sodium phosphate 0.1% and neomycin sulphate 0.5%)
Number of subjects: 65
Study 21292332 — intervention group
Group type: COMPARATOR
Intervention: 10% ichthammol glycerine pack
Number of subjects: 65
Study 19479252 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 10 mg
Number of subjects: 8
Study 19479252 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 20 mg
Number of subjects: 8
Study 19479252 — intervention group
Group type: EXPERIMENTAL
Intervention: GIPET-enhanced oral acyline 40 mg
Number of subjects: 8
Study 17286537 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 352
Study 15179240 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on seat belt use during pregnancy
Number of subjects: 735
Study 11297832 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 108
Study 11297832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 9144824 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach case management team
Number of subjects: 289
Study 9144824 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare (Control)
Number of subjects: 289
Study 9144824 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management team
Number of subjects: 289
Study 9144824 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 289
Study 8190577 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo (Eprex, 600 U/kg per week)
Number of subjects: 80
Study 8190577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30460996 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand bupropion XL 300 mg
Number of subjects: 70
Study 30460996 — intervention group
Group type: COMPARATOR
Intervention: Generic bupropion XL 300 mg
Number of subjects: 70
Study 26356398 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (50 mg/day) for 3 months
Number of subjects: 32
Study 26356398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23518240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 160
Study 23518240 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 160
Study 21547598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC + CRTinact (BMMC therapy only)
Number of subjects: 26
Study 21547598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC + CRTact (BMMC therapy + CRT)
Number of subjects: 26
Study 21547598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC + CRTact and BMMC + CRTinact
Number of subjects: 26
Study 21547598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC + CRTinact
Number of subjects: 26
Study 21547598 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC + CRTact
Number of subjects: 26
Study 18695661 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell transplantation
Number of subjects: 10
Study 18695661 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not enroll in the study)
Number of subjects: 10
Study 16161123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized bone chips supplemented with platelet gel (PG)
Number of subjects: 10
Study 16161123 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized bone chips without gel
Number of subjects: 10
Study 12662013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp incremental cycle ergometry
Number of subjects: 120
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha fetoprotein (AFP) and ultrasonography screening
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical resection
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: intra-arterial chemotherapy
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodality combination and sequential treatment
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: conformal radiotherapy
Number of subjects: 0
Study 11100985 — intervention group
Group type: EXPERIMENTAL
Intervention: tamoxifen
Number of subjects: 0
Study 8960716 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (18, 24, or 30 mg daily)
Number of subjects: 1111
Study 8960716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1111
Study 8960716 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 1111
Study 1404122 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 10
Study 1404122 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 10
Study 4052935 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 37
Study 4052935 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus cisplatin
Number of subjects: 37
Study 30777311 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided waves (500‐kHz bi‐directional axial transmission)
Number of subjects: 15
Study 29432907 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard of care and 4 text messages a week through 6 months (n=108 completing)
Number of subjects: 231
Study 29432907 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care materials at well-child visits through 6 months (n=99 completing)
Number of subjects: 231
Study 27356240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ω‐3 + OLE
Number of subjects: 36
Study 27356240 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk
Number of subjects: 36
Study 27356240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 25194850 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community healthcare workers
Number of subjects: 40
Study 25194850 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 23617982 — intervention group
Group type: EXPERIMENTAL
Intervention: Government-mandated nutrition information
Number of subjects: 687
Study 23617982 — intervention group
Group type: COMPARATOR
Intervention: Industry labelling (voluntary calorie symbols)
Number of subjects: 687
Study 23617982 — intervention group
Group type: COMPARATOR
Intervention: Coke® bottle with calorie amounts per serving
Number of subjects: 687
Study 23617982 — intervention group
Group type: EXPERIMENTAL
Intervention: Coke® bottle with calorie amounts per container
Number of subjects: 687
Study 19959493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 341
Study 19959493 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 5000 IU twice daily)
Number of subjects: 341
Study 19959493 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modalities (both enoxaparin and UFH)
Number of subjects: 341
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily (ALL-500 group)
Number of subjects: 124
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 1000 mg twice daily (ALL-1000 group)
Number of subjects: 124
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test <= 15 in ALL-500 group
Number of subjects: 124
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test > 15 in ALL-500 group
Number of subjects: 124
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test <= 15 in ALL-1000 group
Number of subjects: 124
Study 17669110 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment value of (13)C-urea breath test > 15 in ALL-1000 group
Number of subjects: 124
Study 16478369 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent feedback group (real-time EMG waveform displays)
Number of subjects: 22
Study 16478369 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal feedback group (static terminal EMG waveform displays)
Number of subjects: 22
Study 16478369 — intervention group
Group type: COMPARATOR
Intervention: Control sites (orofacial, no-feedback)
Number of subjects: 22
Study 11999591 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary block with limb placed on thorax
Number of subjects: 81
Study 11999591 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary block with limb placed in abduction
Number of subjects: 81
Study 11999591 — intervention group
Group type: COMPARATOR
Intervention: Transient visualization of the limb position
Number of subjects: 81
Study 15511994 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt-tipped needles
Number of subjects: 204
Study 15511994 — intervention group
Group type: COMPARATOR
Intervention: Sharp-tipped needles
Number of subjects: 204
Study 7534450 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of the MAP administered to Israeli children
Number of subjects: 60
Study 7534450 — intervention group
Group type: COMPARATOR
Intervention: U.S. norms on the MAP
Number of subjects: 60
Study 2231376 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 70
Study 2231376 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate
Number of subjects: 70
Study 20727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 to 0.6 mg/kg)
Number of subjects: 0
Study 20727 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (equipotent doses)
Number of subjects: 0
Study 20727 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone (control)
Number of subjects: 0
Study 29699895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training of auditory processing systems (N = 47)
Number of subjects: 90
Study 29699895 — intervention group
Group type: COMPARATOR
Intervention: Computer games control condition (N = 43)
Number of subjects: 90
Study 29121183 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary EN‐DCR within 2 weeks of presentation
Number of subjects: 32
Study 29121183 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous drainage of lacrimal sac abscess followed by EN‐DCR after the acute episode subsided (control group)
Number of subjects: 32
Study 29121183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 25861099 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day empathy simulation intervention (n=20)
Number of subjects: 40
Study 25861099 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 40
Study 24050859 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 4989
Study 21297074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tifacogin 0.025 mg/kg/h
Number of subjects: 2138
Study 21297074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2138
Study 19380940 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth network with an asynchronous clinical decision support system for health care providers
Number of subjects: 0
Study 19380940 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17672830 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐Bond C&B resin cement with 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40
Study 17672830 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond + Opal resin cement with 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40
Study 17672830 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0.5 mm thick porcelain laminates without resin cement
Number of subjects: 40
Study 17672830 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0.5 mm thick porcelain laminates bonded to dentin
Number of subjects: 40
Study 17672830 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mm thick porcelain laminates bonded to enamel
Number of subjects: 40
Study 17672830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mm thick porcelain laminates bonded to dentin
Number of subjects: 40
Study 17682320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 60
Study 17682320 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E1 (PG E1) at 0.05 microg/kg/min
Number of subjects: 60
Study 10769331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran treatment (gradually increasing daily doses of a bran mixture)
Number of subjects: 12
Study 10769331 — intervention group
Group type: COMPARATOR
Intervention: Usual care (controls)
Number of subjects: 12
Study 9152656 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg o.d.
Number of subjects: 14
Study 9152656 — intervention group
Group type: COMPARATOR
Intervention: Ibopamine 100 mg t.d.s.
Number of subjects: 14
Study 8478672 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk group
Number of subjects: 227